Vimarsana
Biggest News Aggregation in the World

Page 4 - Tim Bartels News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Tim Bartels. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Tim Bartels Today - Breaking & Trending Today

An Iowa school district thinks 4-day weeks may ease staffing concerns - Vimarsana News

An Iowa school district thinks 4-day weeks may ease staffing concerns

The Cardinal school district may join a few others in Iowa that have moved to four-day weeks, all citing a desire to attract students and teachers.

Lewy Body Dementia Center Without Walls - Discovery and Translation Labs: Brain Research - Vimarsana News

Lewy Body Dementia Center Without Walls - Discovery and Translation Labs: Brain Research

Advancing research on a common form of dementia Mayo Clinic researchers have assembled a team of international experts to investigate key proteins involved in Lewy body dementia. Lewy Body Dementia Center Without Walls Investigators from Mayo Clinic's Florida campus are leading a Lewy Body Dementia Center Without Walls research initiative funded by a National Institutes of Health (NIH) specialized center-cooperative agreement grant (U54). The overall goal of the Lewy body dementia multi-institutional Center Without Walls (CWOW) initiative is to deepen the understanding of how the Alzheime...

Source: mayo.edu
Hudson Chamber of Commerce plans to talk renewable energy - Vimarsana News

Hudson Chamber of Commerce plans to talk renewable energy

HUDSON — The Hudson Chamber of Commerce will continue its discussion on renewable energy with a second panel at 8:30 a.m. Tuesday, May 18.

For α-Synuclein Immunotherapy, Is Going Later the Key? - Vimarsana News

For α-Synuclein Immunotherapy, Is Going Later the Key?

04 Apr 2021 α-Synuclein immunotherapy is in its infancy, with few trials posting results yet. The first two completed Phase 2s, of Biogen’s cinpanemab and Prothena and Roche’s prasinezumab, were both negative. However, while the cinpanemab study was fully negative, prasinezumab posted positive results on some secondary motor measures. At the 15th International Conference on Alzheimer’s and Parkinson’s Diseases, held virtually March 9–14, Gennaro Pagano of Roche gave researchers a first look at prespecified subgroup analyses from this study, called PASADENA. It turned out that subg...